The ovarian cancer market was valued at $1.8bn in 2018 across the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan), and it is expected to grow to $6.7bn in the following 10 years, with a compound annual growth rate of 14.4%, according to GlobalData. GlobalData’s latest report, Ovarian Cancer: Opportunity Analysis and Forecasts to 2028,1 states that the main drivers of growth will be the adoption of maintenance therapy across the major markets, poly ADP-ribose polymerase (PARP) inhibitor uptake in the first-line setting, the launch of new pipeline agents, and increased screening rates for genetic markers. In 2028, three PARP inhibitor drugs are expected to have combined revenue of $2.8bn, constituting more than 40% of the global ovarian cancer market. By 2028, another major revenue contributor will be new drug classes - notably, immune checkpoint inhibitors, with five expected to enter the market bringing combined forecasted revenues of around $1.4bn. A major barrier for growth in the ovarian cancer market, however, will be the emerging use of biosimilars and generics for some key marketed products, namely Lynparza and angiogenesis inhibitor Avastin. 1. https://bit.ly/2PA1ItB
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.